INVA - Company ID 0001080014
Innoviva, Inc. trades as INVA and has a market capitalization of $1.64 B, making it the #2297 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $411.33M, up 14.7% from the prior year. This page tracks Innoviva, Inc. through 1,653 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Innoviva, Inc.'s revenue grew from $133.57M to $411.33M, a compound annual growth rate of 13.3%.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-20 |
| New insider ownership | 3 | 2026-05-20 |
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13D/A | - | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-06 |
Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year
Generated $63.4 million in revenue from durable royalties portfolio
Strong royalties portfolio performance with $67.3 million in revenue
The largest companies sharing Innoviva, Inc.'s SEC industry classification (pharmaceutical preparations).
Innoviva, Inc. (INVA) has a market capitalization of $1.64 B as of 2026-07-11, ranking #2297 among US-listed companies.
Innoviva, Inc. reported revenue of $411.33M for fiscal year 2025, an increase of 14.7% year over year.